Compare CABA & XYF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CABA | XYF |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.2M | 260.6M |
| IPO Year | 2019 | 2018 |
| Metric | CABA | XYF |
|---|---|---|
| Price | $2.39 | $6.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $13.50 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 212.9K |
| Earning Date | 11-10-2025 | 11-20-2025 |
| Dividend Yield | N/A | ★ 8.76% |
| EPS Growth | N/A | ★ 49.84 |
| EPS | N/A | ★ 5.72 |
| Revenue | N/A | ★ $1,106,908,607.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.12 |
| Revenue Growth | N/A | ★ 47.14 |
| 52 Week Low | $0.99 | $6.36 |
| 52 Week High | $3.67 | $20.36 |
| Indicator | CABA | XYF |
|---|---|---|
| Relative Strength Index (RSI) | 48.61 | 27.22 |
| Support Level | $2.32 | $6.36 |
| Resistance Level | $2.48 | $7.28 |
| Average True Range (ATR) | 0.14 | 0.36 |
| MACD | -0.00 | 0.14 |
| Stochastic Oscillator | 17.50 | 4.46 |
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.